Benzinga
09 Jan 2026, 14:56 UTC · 36w ago
Verdict
Headline leans bullish. We score KALV +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported strong early sales, high prescriber uptake for its newly approved drug, and positive stock price action.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+70.7%
Price agrees with the score
$27.00 vs $15.82 close before publication (Jan 8) · not market-adjusted
KALV chart →